# PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

> **NCT04054245** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Myelofibrosis Transformation in Essential Thrombocythemia
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Primary Myelofibrosis

## Interventions

- **DRUG:** LOXL2 Inhibitor PAT-1251
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04054245
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-24
- **Primary completion:** 2019-07-24
- **Final completion:** 2019-07-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** "Company is in a process of being taken over by another pharma and the new one has different ideas on how to pursue studies with this drug"
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054245, "PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04054245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*